The Immunohistochemistry (IHC) market is valued at USD 1.9 billion in 2021 and is poised to grow at a significant CAGR of 9.2% over 2022–2028. Since personalized medicine has shown to be quite successful in treating non-small-cell lung cancer patients, its use is anticipated to rise. By providing the most thorough and precise histological subtyping of tumors feasible, immunohistochemistry techniques enable this method of treatment decision-making (supported by predictive immunohistochemistry and the assessment of relevant biomarkers). Additionally, the improved accessibility of immunohistochemical assays that identify mutant proteins (such as BRAF V600E and IDH1 R132H) offers a useful substitute or supplementary method to molecular testing. These methods are valuable novel tools in contemporary cancer care since they are highly reproducible, involve a manageable level of technical and interpretative complexity, and are accessible for comparatively little money. Furthermore, multiplex and mutation-specific immunohistochemistry tests are significant advances that have boosted value in targeted therapy and personalized medicine. The demand for IHC in disease diagnosis has increased significantly due to improvements in IHC methods. The market is growing due to the rise in product approvals and the introduction of technologically sophisticated IHC equipment for illness diagnostics. For instance, in August 2021, the FDA approved Roche’s VENTANA MMR RxDx Panel to identify patients with dMMR solid tumors who are candidates for anti-PD-1 immunotherapy. To improve their market position, businesses keep releasing innovative items which generate income. For instance, in March 2021, Roche introduced the DISCOVERY Green HRP kit to find and characterize cell populations and biomarkers in tissue-based research. The multiplexing capabilities of in situ hybridization and IHC can be increased by using this kit in conjunction with other detection kits. The leading players are launching new products, merging with other companies, expanding regionally, and engaging in other strategic efforts in the field of IHC to address the growing demand for IHC assays in cancer diagnostics. For instance, Biocare Medical LLC introduced the ONCORE Pro in January 2021. This benchtop in vitro diagnostic system is fully automated and is used for In-situ Hybridization (ISH) and IHC applications.
Recent Market Developments:
In August 2021, Roche received FDA approval for VENTANA MMR RxDx companion diagnostic test based on immunohistochemistry for solid tumors that are deficient in the MMR pathway. The test identifies patients eligible for GSK’s anti-PD1 immunotherapy, JEMPERLI.